Evaluation of the Durability of Pain Relief Throughout a 12-Hour Dosing Interval of a Novel, Extended-Release, Abuse-Deterrent Formulation of Oxycodone - Oxycodone DETERx.

CONCLUSION: The evaluation of dosing patterns indicates that this ER oxycodone capsule formulation has durability of effect over the entire 12-hour dosing interval. These data support the use of Oxycodone DETERx ER as a 12-hour dosing formulation. *Xtampza ER is a registered trademark of Collegium that uses DETERx, an abuse deterrent technology also a registered trademark of the owner, Collegium Pharmaceutical, Inc. Canton, MA, USA. PMID: 27025986 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/27025986?dopt=Abstract

Source: Current Medical Research and Opinion - March 31, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research